Five potential unicorns to watch in 2025, according to Forge Global

Investing.com -- The term "Unicorn" refers to a private company that has surpassed a billion dollars in value. In 2024, the number of U.S. companies achieving this status was 56, down from 86 in 2023, according to TechCrunch. Many of these companies operate within the fields of artificial intelligence (AI), cybersecurity, and health tech.

Five companies listed on Forge Global are currently being closely watched for their potential to achieve Unicorn status in 2025. These companies, known as "Soonicorns," have past or current valuations of $600 million or more, but have not yet reached the $1 billion threshold necessary to be considered a unicorn company.

Among these potential unicorns is Cresta, an AI platform for company contact centers. Over the past two years, Cresta has almost quadrupled its annual recurring revenue and doubled its customer base. The company has a current valuation of $750.8 million, as of February 11, 2025.

Gecko Robotics, an AI and robotics firm, is another potential unicorn. The company uses robots to collect data on equipment used in various industries, including defense, oil and gas, steel, and mining. Gecko Robotics’ valuation stands at $613.6 million as of February 11, 2025.

Cybereason, a cybersecurity company, provides software and consulting services to prevent and analyze online attacks. Following a merger with Trustwave in November 2024, the company’s valuation stands at $733.3 million as of February 11, 2025.

RapidAI, a healthcare AI company, uses AI for brain imaging analysis, aiming to improve patient care for strokes, aneurysms, and pulmonary embolisms. As of January 31, 2025, the company’s valuation stands at $421.4 million.

Finally, Alto Pharmacy, an online pharmacy that offers home delivery of medications, has a valuation of $292.7 million as of January 31, 2025. The company launched Alto Technologies in October 2024, a suite of pharmacy technologies that combines pharmacist expertise with automation and AI to improve efficiency in providing prescription drugs.

As these companies continue to grow, the potential for them to achieve unicorn status in 2025 remains a possibility to watch.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.